News

European Agency Grants PRIME Access to GBT440 Therapy for Treatment of SCD

The European Medicines Agency (EMA) has granted GBT440 — Global Blood Therapeutics’ lead drug candidate for sickle cell disease (SCD) — access to its Priority Medicines (PRIME) program. GBT440 is an oral, once-daily drug being developed to specifically inhibit hemoglobin polymerization and the consequent sickling of red blood cells, the hallmark…

Sickle Cell Disease Association of America Receives $11.6 Million Grant for Follow–Up Services

The Health Resources and Services Administration (HRSA), part of the U.S. Department of Health and Human Services, has awarded the Sickle Cell Disease Association of America (SCDAA) a $2.9 million annual grant for the next four years to establish a national infrastructure to ensure sickle cell disease (SCD) patients receive appropriate follow–up care…

Multidisciplinary Care Team Greatly Reduces Risk in Pregnant SCD Patients in Low-income Countries

According to a study published in the American Journal of Hematology, the presence of a multidisciplinary clinical team can dramatically reduce maternal and perinatal mortality rates in pregnant women with sickle cell disease (SCD), especially in under-developed and low-income countries. In recent decades, medical advances have significantly improved the survival of those…